Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entera Bio Ltd.ENTX · Entity 5464 | Director | January 01, 2024 | January 03, 2024 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entera Bio Ltd.
Report date January 01, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2034-01-01 | Direct | 108,333 |
Reported balance
After 2024-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-01 · Grant · Acquired 108,333 · Balance 108,333 F1: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001213900-26-069245 · marketforms-73182.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2036-06-14 F1 · derivative.exercise_date: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001213900-25-054283 · marketforms-69813.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-24-051376 · marketforms-66259.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:21 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 108,333 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001178913-24-000055 · zk2430736.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,333 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares Expires 2034-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001213900-23-047472 · ownership.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:23 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 89,041 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001178913-23-000055 · zk2328964.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,041 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares Expires 2033-01-02 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023. Read SEC document |
| June 08, 2022 Filed Jun 9, 2022 20:10 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001213900-22-031991 · ownership.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:08 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 107,557 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000089 · zk2227044.xml · derivative · entry 2 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,557 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 107,557 shares Expires 2032-01-01 F2 · derivative.exercise_date: The options vest ratably on a quarterly basis over a three-year period that commenced on January 1, 2022. Read SEC document |
| January 01, 2022 Filed Jan 11, 2022 21:08 UTC | Entera Bio Ltd. ENTX · Entity 5464 | GrantStock Option (right to buy) · Derivative | 35,852 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001178913-22-000089 · zk2227044.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,852 Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,852 shares Expires 2032-01-01 F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2022. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 00:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039683 · doc4.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 17:38 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035848 · doc4.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 10, 2020 Filed Jan 14, 2020 00:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-003239 · doc4.xml · nonDerivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards ("RSUs"), each one of which represents a contingent right to receive one share of the Issuer's common stock. 3/24th of the shares were vested upon grant and 1/24th of the shares vest monthly thereafter, beginning on February 10, 2020. Settlement for the RSUs is deferred until the earliest to occur of (i) the Reporting Person's termination of service, (ii) death, (iii) disability and (iv) a change in control of the Issuer. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,491 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003239 · doc4.xml · derivative · entry 3 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,491 Underlying: Common Stock · 10,491 shares Expires 2029-04-28 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F6 · price: Received in the Merger in exchange for a stock option to acquire 55,000 shares of ArTara Sub common stock for $1.75 per share. F5 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly following April 29, 2019, for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jan 14, 2020 00:18 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,399 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-003239 · doc4.xml · derivative · entry 2 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,399 Underlying: Common Stock · 12,399 shares Expires 2028-12-31 F2 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F4 · price: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share. F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly thereafter for so long as the Reporting Person provides continuous service to the Issuer. Read SEC document |
| January 09, 2020 Filed Jun 11, 2020 17:37 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,399 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0001209191-20-035847 · doc4a.xml · derivative · entry 1 GARCEAU ROGER · CIK 0001451767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,399 Underlying: Common Stock · 12,399 shares Expires 2028-12-23 F1 · date: On September 23, 2019, the Issuer entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") as amended on November 19, 2019, with the Issuer, REM 1 Acquisition, Inc. ("Merger Sub") and ArTara Subsidiary, Inc. ("ArTara Sub"). On January 9, 2020 (the "Effective Time"), Merger Sub was merged with and into ArTara Sub, with ArTara Sub surviving as a wholly owned subsidiary of the Issuer. F3 · price: Received in the Merger in exchange for a stock option to acquire 65,000 shares of ArTara Sub common stock for $1.75 per share. F2 · derivative.exercise_date: The Option Shares shall vest in forty eight (48) approximately equal increments of two hundred fifty eight (258) whole Option Shares beginning on the first day of the first calendar month following December 24, 2018, and then on the first day of each of the next forty seven (47) months thereafter (each a "Vesting Date"), if Reporting Person has remained continuously engaged by the Issuer or any Affiliate through such Vesting Date; provided that, on the last such Vesting Date (being December 1, 2022), all of the Option Shares which had not vested by then will vest and become exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.